Market Cap
US$6.8b
Last Updated
2020/08/09 00:13 UTC
Data Sources
Company Financials +
Executive Summary
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
Snowflake Analysis
Reasonable growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Bruker's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BRKR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.1%
BRKR
-0.4%
US Life Sciences
2.5%
US Market
1 Year Return
7.6%
BRKR
35.9%
US Life Sciences
16.3%
US Market
Return vs Industry: BRKR underperformed the US Life Sciences industry which returned 35.9% over the past year.
Return vs Market: BRKR underperformed the US Market which returned 16.3% over the past year.
Shareholder returns
| BRKR | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.1% | -0.4% | 2.5% |
| 30 Day | 11.4% | 6.8% | 5.6% |
| 90 Day | 13.0% | 21.0% | 16.4% |
| 1 Year | 8.0%7.6% | 36.1%35.9% | 18.8%16.3% |
| 3 Year | 62.6%60.5% | 104.7%103.4% | 45.1%35.7% |
| 5 Year | 124.1%119.1% | 154.2%150.9% | 75.8%56.8% |
Price Volatility Vs. Market
How volatile is Bruker's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall St
Announcing: Bruker (NASDAQ:BRKR) Stock Increased An Energizing 153% In The Last Five Years8 months ago | Simply Wall St
Can Bruker Corporation (NASDAQ:BRKR) Maintain Its Strong Returns?8 months ago | Simply Wall St
Does Bruker (NASDAQ:BRKR) Have A Healthy Balance Sheet?Valuation
Is Bruker undervalued compared to its fair value and its price relative to the market?
41.3x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BRKR ($44.13) is trading above our estimate of fair value ($36.84)
Significantly Below Fair Value: BRKR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BRKR is good value based on its PE Ratio (41.3x) compared to the US Life Sciences industry average (43.1x).
PE vs Market: BRKR is poor value based on its PE Ratio (41.3x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: BRKR is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: BRKR is overvalued based on its PB Ratio (7.4x) compared to the US Life Sciences industry average (6.3x).
Next Steps
Future Growth
How is Bruker forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
25.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BRKR's forecast earnings growth (25% per year) is above the savings rate (2.2%).
Earnings vs Market: BRKR's earnings (25% per year) are forecast to grow faster than the US market (23.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BRKR's revenue (7.1% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: BRKR's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BRKR's Return on Equity is forecast to be high in 3 years time (21.3%)
Next Steps
Past Performance
How has Bruker performed over the past 5 years?
14.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BRKR has high quality earnings.
Growing Profit Margin: BRKR's current net profit margins (8.4%) are lower than last year (9.6%).
Past Earnings Growth Analysis
Earnings Trend: BRKR's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: BRKR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BRKR had negative earnings growth (-13%) over the past year, making it difficult to compare to the Life Sciences industry average (10.7%).
Return on Equity
High ROE: BRKR's Return on Equity (18.2%) is considered low.
Next Steps
Financial Health
How is Bruker's financial position?
Financial Position Analysis
Short Term Liabilities: BRKR's short term assets ($2.0B) exceed its short term liabilities ($749.7M).
Long Term Liabilities: BRKR's short term assets ($2.0B) exceed its long term liabilities ($1.3B).
Debt to Equity History and Analysis
Debt Level: BRKR's debt to equity ratio (110.6%) is considered high.
Reducing Debt: BRKR's debt to equity ratio has increased from 46.2% to 110.6% over the past 5 years.
Debt Coverage: BRKR's debt is well covered by operating cash flow (23.5%).
Interest Coverage: BRKR's interest payments on its debt are well covered by EBIT (20.2x coverage).
Balance Sheet
Next Steps
Dividend
What is Bruker current dividend yield, its reliability and sustainability?
0.36%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BRKR's dividend (0.36%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.62%).
High Dividend: BRKR's dividend (0.36%) is low compared to the top 25% of dividend payers in the US market (4.36%).
Stability and Growth of Payments
Stable Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: BRKR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BRKR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
10.3yrs
Average management tenure
CEO
Frank Laukien (60 yo)
29.5yrs
Tenure
US$4,909,641
Compensation
Dr. Frank H. Laukien, Ph.D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut ...
CEO Compensation Analysis
Compensation vs Market: Frank's total compensation ($USD4.91M) is below average for companies of similar size in the US market ($USD7.26M).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 29.5yrs | US$4.91m | 25.88% $ 1.7b | |
| CFO, VP & Corporate Controller | 2.42yrs | US$1.25m | 0.0014% $ 98.0k | |
| Executive VP and President of Bruker Nano Group & Bruker Nano Surfaces Division | 5.08yrs | US$1.70m | 0.019% $ 1.3m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 7.58yrs | US$1.33m | 0.043% $ 2.9m | |
| President of Bruker BioSpin Group | 2.25yrs | US$950.03k | 0.0015% $ 103.4k | |
| Director of Investor Relations & Corporate Development | no data | no data | no data | |
| President of Chemical Analysis Division | 10.33yrs | US$1.10m | no data | |
| Treasurer & Director of Investor Relations | 12.42yrs | no data | no data | |
| President of Bruker Optics Division & Managing Director of Bruker Optik GmbH | 10.58yrs | no data | no data | |
| President and CEO of Bruker Energy & Supercon Technologies | 12.33yrs | US$967.91k | 0.014% $ 946.5k | |
| Secretary | no data | no data | no data |
10.3yrs
Average Tenure
60yo
Average Age
Experienced Management: BRKR's management team is seasoned and experienced (10.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 29.5yrs | US$4.91m | 25.88% $ 1.7b | |
| Independent Director | 5yrs | US$218.01k | 0.0052% $ 348.6k | |
| Independent Director | 4.75yrs | US$203.01k | 0.0052% $ 352.6k | |
| Independent Director | 13.25yrs | US$206.01k | 0.032% $ 2.2m | |
| Independent Lead Director | 16.42yrs | US$198.01k | 0.047% $ 3.2m | |
| Independent Director | 3.25yrs | US$203.01k | 0.0067% $ 454.0k | |
| Independent Director | 5yrs | US$193.01k | 0.0052% $ 352.6k | |
| Independent Director | 5.58yrs | US$194.01k | 0.0022% $ 152.0k | |
| Independent Director | 4.25yrs | US$193.01k | 0.0061% $ 411.4k |
5.0yrs
Average Tenure
63yo
Average Age
Experienced Board: BRKR's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BRKR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Bruker Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bruker Corporation
- Ticker: BRKR
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.756b
- Shares outstanding: 153.09m
- Website: https://www.bruker.com
Number of Employees
Location
- Bruker Corporation
- 40 Manning Road
- Billerica
- Massachusetts
- 1821
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BRKR | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Aug 2000 |
| BKD | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Aug 2000 |
| BRKR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Shares | MX | MXN | Aug 2000 |
Biography
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/09 00:13 |
| End of Day Share Price | 2020/08/07 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.